Clinical Scorecard: Efficacy and Safety of Carfilzomib, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Retrospective Study from China

At a Glance

Key Highlights

• Overall response rate (ORR) of 82.4% in the study cohort.
• Median progression-free survival (PFS) of 13 months.
• High incidence of hematologic toxicities (73.5% of patients).
• 58.8% of patients experienced grade 3/4 adverse events.
• Significant influence of high-risk cytogenetics and prior daratumumab exposure on treatment response.

Guideline-Based Recommendations

Diagnosis

• Confirmed diagnosis of multiple myeloma according to IMWG criteria.

Management

• KPd regimen administered in 28-day cycles with specific dosing for carfilzomib, pomalidomide, and dexamethasone.

Monitoring & Follow-up

• Careful monitoring of hematologic toxicities and adverse events.

Risks

• High incidence of hematologic toxicities necessitating management.

Patient & Prescribing Data

34 RRMM patients, median age 65 years, all bortezomib-exposed, 91.2% lenalidomide-exposed and refractory.

KPd effective in heavily pretreated patients, including those with lenalidomide-refractory disease.

Clinical Best Practices

• Assess cytogenetic risk before treatment.
• Implement supportive care measures for managing adverse events.
• Regularly evaluate treatment response at the end of each cycle.

Related Resources & Content

• Study Source